Table 4. Pharmacokinetic Parameters for Compound 5 in ICR Mice Following Intravenous (2 mg/kg) and Oral (10 mg/kg) Administration.
| Compound 5 |
||
|---|---|---|
| PK Parametersa | p.o. | i.v. |
| Cmax (ng·mL–1) | 195 ± 61 | 483 ± 143 |
| t1/2 (h) | 2.19 ± 0.29 | 2.53 ± 0.25 |
| MRT (h) | 3.09 ± 0.09 | 2.24 ± 0.23 |
| AUC (ng·h·mL–1) | 791 ± 338 | 576 ± 54 |
| Clint (mL·min–1·kg–1) | 58.2 ± 5.7 | |
| Vd (L·kg–1) | 12.8 ± 2.5 | |
| F (%) | 27.4 ± 11.7 | |
a
Cmax, maximum concentration of drug in blood plasma; t1/2, the elimination half-life of drug; MRT, mean residence time; AUC, area under the curve; Clint, hepatic clearance; Vd, apparent volume of distribution; F, oral bioavailability.